BLS 0597
Latest Information Update: 22 Mar 2007
At a glance
- Originator Boston Life Sciences
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 22 Mar 2007 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 17 Jun 2002 This compound is still in active development
- 13 Sep 1999 New profile